From GlobeNewswire: 2025-04-30 02:00:00

Karolinska Development AB (Nasdaq Stockholm: KDEV) releases its Interim Report for January-March 2025. The report highlights high developmental activity in portfolio companies, with significant advancements noted during the first quarter.

Key events in the first quarter include AnaCardio’s funding of SEK 205 million and positive results from a phase 1b/2a study. Dilafor completed successful regulatory meetings for tafoxiparin, while Promimic reported reduced bacterial growth on HAnano Surface.

Umecrine Cognition faced delays in a clinical trial due to production issues. However, recent preclinical data showed positive results for golexanolone in Parkinsonian symptoms at a conference in Vienna.

Financially, Karolinska Development reported a net loss of SEK -14.2 million for the first quarter, with a decrease in total fair value of the portfolio. Cash and cash equivalents increased by SEK 9.0 million, reaching SEK 51.1 million by the end of March 2025.



Read more at GlobeNewswire:: Interim Report – January-March 2025